Herbs & Supplements

References

Abbott PJ. Comfrey: assessing the low-dose health risk. Medical Journal of Australia. 1988;149(11-12):678-682.

Altamirano JC, Gratz SR, Wolnik KA. Investigation of pyrrolizidine alkaloids and their N-oxides in commercial comfrey-containing products and botanical materials by liquid chromatography electrospray ionization mass spectrometry. J AOAC Int. 2005;88(2):406-412.

American Academy of Pediatrics. Comfrey. February 25, 2004. Available at: http://www.ny2aap.org/herbs/prod06.htm. Accessed September 30, 2004.

American Cancer Society. Comfrey. 2002. Available at: http://www.cancer.org/docroot/ETO/content/ETO_5_3X_Comfrey.asp?sitearea=ETO. Accessed September 30, 2004.

Anon. AAFCO framework for regulatory action on commercial animal feeds containing comfrey. FDA Veterinarian Newsletter. March/April 2003;28(2). Available at: http://www.fda.gov/cvm/index/fdavet/2003/Mar-Apr03.htm . Accessed August 6, 2004.

Anon: Comfrey. In: DerMarderosian A, Beutler JA, eds. Facts and Comparisons: The Review of Natural Products. St. Louis, MO, Facts and Comparisons. October 1995.

Association of American Feed Control Officials, Inc. Target ingredient announcement. AAFCO recommended enforcement event. Enforcement strategy for marketed ingredients (ESMI) working group. August 2002. Available at: www.aafco.org/comfrey.html. Accessed September 30, 2004.

Awang DV, Dawson BA, Fillion J, Girad M, Kindack D. Echimidine content of commercial comfrey (Symphytum spp.- Boraginaceae) Journal of Herbs, Spices and Medicinal Plants. 1993;2(1):21-34.

Bach N, Thung SN, Schaffner F. Comfrey herb tea-induced hepatic veno-occlusive disease. American Journal of Medicine. 1989;87(1):97-99.

Barrett S. FDA, FTC blast comfrey marketers. Consumer Health Digest. National Council Against Health Fraud and QuackWatch. July 23, 2001. Available at: http://www.ncahf.org/digest/01-30.html. Accessed September 30, 2004.

Bergner P. Symphytum: Comfrey, coltsfoot, and pyrrolizidine alkaloids. Medical Herbalism. 1989;1(1):1,3-5.

Bergner P. Symphytum: Comfrey is comfrey is comfrey: or is it? Medical Herbalism. 1994;6(1):13.

Bergner P. Symphytum: Hepatotoxicity of pyrrolizidine alkaloids. Medical Herbalism.1994;6(1):10.

Betz JM, Eppley RM, Taylor WC, Andrzejewski D. Determination of pyrrolizidine alkaloids in commercial comfrey products (Symphytum sp.). Journal of Pharmaceutical Sciences. 1994;83(5):649-653.

Brinker F. Coming clean on supplements designated the "dirty dozen". Alternative Medicine Alert. August 2004. Available at: http://www.ahcpub.com/ahc_root_htm/hot/archive/2004/ama082004.html. Accessed September 30, 2004.

Brinker F. Herb Contraindications and Drug Interactions. Sandy, Oregon: Eclectic Institute, 1997.

Burch D, Cupp MJ. Comfrey. In Cupp, MJ. Ed. Toxicology and Clinical Pharmacology of Herbal Products. 2000. Totowa, NJ: Humana Press, Inc.

Consumer Reports. Dangerous supplements: still at large. Consumer Reports. May 2004.

Couet CE, Crews C, Hanley AB. Analysis, separation, and bioassay of pyrrolizidine alkaloids from comfrey (Symphytum officinale). Natural Toxins. 1996;4(4):163-167.

Culvenor CCJ. Estimated Intakes Of Pyrrolizidine Alkaloids By Humans. A Comparison With Dose Rates Causing Tumors In Rats. Journal of Toxicology and Environmental Health. 1983;11(4):625-635.

Dasgupta A. Review of abnormal laboratory test results and toxic effects due to use of herbal medicines. American Journal of Clinical Pathology. 2003;120(1):127-137.

Duke JA. Symphytum peregrinum Lebed. Handbook of Energy Crops. 1983. Unpublished. Available at: http://www.hort.purdue.edu/newcrop/duke_energy/ Symphytum_peregrinum.html. Accessed: September 30, 2004.

Foster S, Tyler VE. Tyler's Honest Herbal: A Sensible Guide to the Use of Herbs and Related Remedies. 3rd ed., Binghamton, NY: Haworth Herbal Press, 1993.

Fu PP, Yang YC, Xia Q, Chou MW, Cui YY, Lin G. Pyrrolizidine alkaloids - tumorigenic components in Chinese herbal medicines and dietary supplements. Journal of Food and Drug Analysis, 2002;10(4):198-211.

Furmanowa M, Guzewska J, Beldowska B. Mutagenic effects of aqueous extracts of Symphytum officinale L. and of its alkaloidal fractions. Journal Applied Toxicology. 1983;3(3):127-130.

Grieve M. Comfrey. In: A Modern Herbal. New York: Dover Publishers, 1971. Available at: http://www.botanical.com/botanical/mgmh/mgmh.html Posted 1995. Accessed September 30, 2004.

Grube B, Grunwald J, Krug L, Staiger C. Efficacy of a comfrey root (Symphyti offic. radix) extract ointment in the treatment of patients with painful osteoarthritis of the knee: results of a double-blind, randomised [sic], bicenter, placebo-controlled trial. Phytomedicine. 2007;14(1):2-10.

Haughton C. Symphytum officinale. Revised May 17, 2004. Available at: http://www.purplesage.org.uk/profiles/comfrey.htm. Accessed September 30, 2004.

Herbs2000. Comfrey. No date given. Available at: http://www.herbs2000.com/herbs/herbs_comfrey.htm. Accessed September 30, 2004.

Hirono I, Mori H, Haga M. Carcinogenic activity of Symphytum officinale. Journal of the National Cancer Institute. 1978;61(3):865-869.

Hoffmann DL. Comfrey. Herbal Materia Medica. No date given. Available at: http://www.healthy.net/asp/templates/article.asp?PageType=article&ID=1648. Accessed September 30, 2004.

Huxtable RJ. The harmful potential of herbal and other plant products. Drug Safety. 1990;5(Suppl 1):126-136.

Huxtable RJ, Awang DV. Pyrrolizidine poisoning. [Letter] American Journal of Medicine. 1990;89(4):547-548.

International Programme [sic] on Chemical Safety. Environmental health criteria 80. Pyrrolizidine alkaloids. World Health Organization. 1988. Available at: http://www.inchem.org/documents/ehc/ehc/ehc080.htm.. Accesses October 5, 2004.

Jellin JM, Gregory P, Batz F, Hitchens K, et al, eds. Pharmacist's Letter/Prescriber's Letter. Natural Medicines Comprehensive Database, 3rd Edition. Stockton CA: Therapeutic Research Facility, 2000.

Klepser TB, Klepser ME. Unsafe and potentially safe herbal therapies. American Journal of Health System Pharmacy. 1999;56:125-138.

Koll R, Klingenburg S. Therapeutic characteristance [sic] and tolerance of topical comfrey preparations. Results of an observational study of patients. [Article in German] Fortschr Med Orig. 2002;120(1):1-9.

Kucera M, Barna M, Horacek O, Kalal J, Kucera A, Hladikova M. Topical symphytum herb concentrate cream against myalgia: a randomized controlled double-blind clinical study. Advanced Therapy. 2005;22(6):681-692.

Lafranconi WM, Huxtable RJ. Hepatic metabolism and pulmonary toxicity of monocrotaline using isolated perfused liver and lung. Biochemistry and Pharmacology. 1984;33(15):2479-2484.

Lafranconi WM, Ohkuma S, Huxtable RJ. Biliary excretion of novel pneumotoxic metabolites of the pyrrolizidine alkaloid, monocrotaline. Toxicon. 1985;23(6):983-992.

Larrey D. Liver involvement in the course of phytotherapy. [Article in French] Presse Medicale. 1994;23(15):691-693.

Lewis CJ. FDA advises dietary supplement manufacturers to remove comfrey products from the market. [letter]. July 6, 2001. Available at: http://vm.cfsan.fda.gov/~dms/dspltr06.html Accessed February 3, 2003.

Manteiga R, Park DL, Ali SS. Risks associated with consumption of herbal teas. Review of Environmental Contaminants and Toxicology. 1997;150:1-30.

Mattocks AR. Toxic pyrrolizidine alkaloids in comfrey. Lancet. 1980;2(8204):1136-1137.

McDermott WV, Ridker PM. The Budd-Chiari syndrome and hepatic veno-occlusive disease. Recognition and treatment. Archives of Surgery. 1990;125(4):525-527.

McGuffin M, Hobbs C, Upton R, Goldberg A, eds. American Herbal Product Association's Botanical Safety Handbook. Boca Raton, FL: CRC Press; 1997.

Mei N, Guo L, Fu PP, Heflich RH, Chen T. Mutagenicity of comfrey (Symphytum Officinale) in rat liver. British Journal of Cancer. 2005;92(5):873-875.

Mei N, Guo L, Zhang L, et al. Analysis of gene expression changes in relation to toxicity and tumorigenesis in the livers of Big Blue transgenic rats fed comfrey (Symphytum officinale). BMC Bioinformatics. 2006;7(Suppl 2):S16.

Nascimento MA, Silva AK, Franca LC, Quignard EL, Lopez JA, Almeida MG Turnera ulmifolia L. (Turneraceae): preliminary study of its antioxidant activity. Bioresour Technol. 2006;97(12):1387-1391.

Panter KE, James LF. Natural plant toxicants in milk: a review. Journal of Animal Sciences. 1990;68(3):892-904.

Prakash AS, Pereira TN, Reilly PE, Seawright AA. Pyrrolizidine alkaloids in human diet. Mutation Research. 1999;443(1-2):53-67.

Predel HG, Giannetti B, Koll R, Bulitta M, Staiger C. Efficacy of a comfrey root extract ointment in comparison to a diclofenac gel in the treatment of ankle distortions: results of an observer-blind, randomized, multicenter study. Phytomedicine. 2005;12(10):707-714.

Ridker PN, McDermott WV. Hepatotoxicity due to comfrey herb tea. [Letter] American Journal of Medicine. 1989;87(6):701.

Ridker PM, Ohkuma S, McDermott WV, Trey C, Huxtable RJ. Hepatic venocclusive disease associated with the consumption of pyrrolizidine-containing dietary supplements. Gastroenterology. 1985;88(4):1050-1054.

Rode D. Comfrey toxicity revisited. Trends in Pharmacological Science. 2002;23(11):497-499.

Roitman JN. Comfrey and liver damage. Lancet. 1981;1(8226):944.

Roulet M, Laurini R, Rivier L, Calame A. Hepatic veno-occlusive disease in newborn infant of a woman drinking herbal tea. Journal of Pediatrics. 1988;112(3):433-436.

Shipochliev T. Uterotonic action of extracts from a group of medicinal plants. [Article in Bulgarian] Vet Med Nauki. 1981;18(4):94-98.

Shipochliev T, Dimitrov A, Aleksandrova E. [Anti-inflammatory action of a group of plant extracts [Article in Bulgarian] Vet Med Nauki. 1981;18(6):87-94.

Sievers AF. The Herb Hunter's Guide. Misc Publication No. 77. 1930. U.S. Department of Agriculture. Washington, DC.

Smith LW, Culvenor CC. Plant sources of hepatotoxic pyrrolizidine alkaloids. Journal of Natural Products. 1981;44(2):129-152.

Sommer M. Hepatic veno-occlusive disease and drinking of herbal teas. Journal of Pediatrics. 1989;115(4):659-660.

Steenkamp V, Stewart MJ, Zuckerman M. Clinical and analytical aspects of pyrrolizidine poisoning caused by South African traditional medicines. Therapeutic Drug Monitoring. 2000;22(3):302-306.

Stegelmeier BL, Edgar JA, Colegate SM, Gardner DR, Schoch TK, Coulombe RA, Molyneux RJ. Pyrrolizidine alkaloid plants, metabolism and toxicity. Journal of Natural Toxins. 1999;8(1):95-116.

Stewart MJ, Steenkamp V. Pyrrolizidine poisoning: a neglected area in human toxicology. Therapeutic Drug Monitoring. 2001;23(6):698-708.

Stickel F, Seitz HK. The efficacy and safety of comfrey. Public Health and Nutrition. 2000;3(4A):501-508.

Teynor, TM, Putnam, DH, Doll JD, Kelling KA, Oelke, D.J. Undersander DJ, Oplinger ES. Comfrey. Updated November 17, 1997. Available at: http://www.hort.purdue.edu/newcrop/afcm/comfrey.html. Accessed September 30, 2004.

Weston CF, Cooper BT, Davies JD, Levine DF. Veno-occlusive disease of the liver secondary to ingestion of comfrey. British Medical Journal (Clinical Research Edition). 1987;295(6591):183.

Wuilloud JCA, Gratz SR, Gamble BM, Wolnik KA. COMFREY I: Simultaneous analysis of hepatotoxic pyrrolizidine alkaloids and N-oxides in comfrey root by LC-ion trap mass spectrometry. [Poster abstract A-73] Presented at the 10th FDA Science Forum. May 18-19, 2004. Washington, D.C.

Wuilloud JCA, Gratz SR, Wolnik KA. COMFREY II: Investigation of pyrrolizidine alkaloids and their N-oxides in commercial comfrey-containing products and botanical materials by LC-ESI-MS. [Poster abstract A-73] Presented at the 10th FDA Science Forum. May 18-19, 2004. Washington, D.C.

Yeong ML, Clark SP, Waring JM, Wilson RD, Wakefield SJ. The effects of comfrey derived pyrrolizidine alkaloids on rat liver. Pathology. 1991;23(1):35-38.

Yeong ML, Swinburn B, Kennedy M, Nicholson G. Hepatic veno-occlusive disease associated with comfrey ingestion. Journal of Gastroenterology and Hepatology. 1990;5(2):211-214.

Yeong ML, Wakefield SJ, Ford HC. Hepatocyte membrane injury and bleb formation following low dose comfrey toxicity in rats. International Journal of Experimental Pathology. 1993;74(2):211-217.

Last Revised August 10, 2007